{"url_path":"/sec/pths/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1919246/0001919246-26-000078-index.html","accession_number":"0001919246-26-000078","cik":"0001919246","ticker":"PTHS","issuer_name":"Pelthos Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1919246/0001919246-26-000078-index.html","primary_entity_key":"0001919246","primary_entity_name":"Pelthos Therapeutics Inc."},"word_count":111,"has_tables":true,"body_markdown":"Item 9.01. Financial Statements and Exhibits.\n\nThe exhibits listed in the following Exhibit Index are filed as part of this report:\n\nExhibit No.Description\n\n10.1\n[Separation and Release Agreement between Pelthos Therapeutics Inc. and Francis Knuettel II, dated May 15, 2026.](pths-20250515xexhibit101.htm)\n\n16.1\n[Letter from CBIZ CPAs P.C. to the SEC dated May 18, 2026](pths-20250518xexhibit161.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: May 21, 2026Pelthos Therapeutics Inc.\n\nBy:/s/ John M. Gay\n\nName:John M. Gay\n\nTitle:Chief Financial Officer"}